Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 563 results found since Jan 2013.

Mortality risk in atrial fibrillation: the role  of aspirin, vitamin K and non-vitamin K antagonists
Conclusion Non vitamin K oral anticoagulants are   associated with a higher risk on all-cause mortality, particularly in men and in patients with higher stroke risk.
Source: International Journal of Clinical Pharmacy - October 7, 2019 Category: Drugs & Pharmacology Source Type: research

Thromboembolism after electrical isolation of the left atrial appendage: a new indication for interventional closure?
ConclusionAfter electrical LAAI for rhythm control in AF patients, interventional LAAC was associated with fewer thromboembolic complications when compared with OAC.
Source: Europace - June 23, 2019 Category: Cardiology Source Type: research

Prevalence and predictors of inappropriate apixaban dosing in patients with non-valvular atrial fibrillation at a large tertiary academic medical institution
ConclusionIn patients with NVAF receiving apixaban for stroke prevention in this real-world analysis,>  80% were prescribed an appropriate dosage of apixaban. Proactive procedures, such as integrating an electronic dosing algorithm, educating healthcare providers, and involving clinical pharmacists in medication review, may help ensure the use of appropriate apixaban dosages.
Source: Drugs and Therapy Perspectives - December 4, 2019 Category: Drugs & Pharmacology Source Type: research

Biomarker-Based Risk Prediction With The ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation
Conclusions: The biomarker-based ABC-AF scores showed better discrimination than traditional risk scores and were recalibrated for precise risk estimation in patients not receiving oral anticoagulation. They can now provide improved decision support regarding treatment of an individual patient with AF.PMID:33849281 | DOI:10.1161/CIRCULATIONAHA.120.053100
Source: Circulation - April 14, 2021 Category: Cardiology Authors: Alexander P Benz Ziad Hijazi Johan Lindb äck Stuart J Connolly John W Eikelboom Jonas Oldgren Agneta Siegbahn Lars Wallentin Source Type: research

Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin  + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research

Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study
ConclusionsThe incidence of NVAF increased between 2009 and 2015, before plateauing. Underprescribing of OACs in NVAF is associated with a range of comorbidities, ethnicity, and socioeconomic factors, demonstrating the need for initiatives to reduce inequalities in the care for AF patients.
Source: PLoS Medicine - June 7, 2022 Category: Internal Medicine Authors: Alyaa M. Ajabnoor Source Type: research

Is a Routine Head CT after IV-tPA Therapy Medically Necessary? (P03.170)
CONCLUSIONS: In clinical practice, the risk of symptomatic ICH after IV-tPA is low. GRASPS scores may be helpful in identifying patients at higher risk for ICH but it is not sufficiently sensitive to guide a selective use for post-therapy surveillance imaging. A protocol requiring repeat neuroimaging at 24 hr after IV-tPA is not supported by clinical practice data. Neuroimaging after IV-tPA should focus on vascular imaging needed for determining the mechanism and treatment plan and to evaluate the cause of clinical deterioration after therapy.Disclosure: Dr. Sehgal has nothing to disclose. Dr. Mehndiratta has nothing to di...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sehgal, S., Mehndiratta, P., Talahma, M., Eisele, S., Sila, C. Tags: P03 Cerebrovascular Disease III Source Type: research

Novel oral anticoagulants in gastroenterology practice
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with a 5-fold increase in the risk of ischemic stroke, and AF-related strokes have worse outcomes than those not associated with AF. Warfarin reduces the risk of stroke in patients with AF by approximately two-thirds and is more effective than aspirin or dual antiplatelet therapy with aspirin and clopidogrel. Although effective, warfarin has limitations that complicate its use. These include unpredictable pharmacokinetics and pharmacodynamics related to genetic polymorphisms and to variations in dietary vitamin K intake and numerous ...
Source: Gastrointestinal Endoscopy - May 31, 2013 Category: Gastroenterology Authors: Jay Desai, Christopher B. Granger, Jeffrey I. Weitz, James Aisenberg Tags: Review Articles Source Type: research

Antithrombotic Therapy for Patients with Atrial Fibrillation and Atherothrombotic Vascular Disease: Striking the Right Balance between Efficacy and Safety.
Abstract Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is estimated to affect 1.5 to 2.0% of the general population, i.e., at least 100 million people worldwide.(1) Left untreated, patients with nonvalvular AF (NVAF) are exposed to an annual risk of thromboembolic stroke of approximately 5%, resulting in 5 million AF-related strokes each year.(1) Properly dosed anticoagulation (e.g., warfarin adjusted to an international normalized ratio [INR] of 2.0 to 3.0) is extremely effective in preventing AF-related strokes, reducing risk by two-thirds compared with no therapy, and by one-half compared to ...
Source: Circulation - July 16, 2013 Category: Cardiology Authors: Patrono C, Andreotti F Tags: Circulation Source Type: research

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Conclusion: Considering their pharmacological properties, their efficacy and bleeding complications, the new oral agents offer a net favourable clinical profile in orthopedic surgery, atrial fibrillation, acute coronary syndrome and increase the risk of bleeding in critically ill patients. Further studies are necessary to determine the long term safety and to identify the specific reversal agents of these new drugs.
Source: Thrombosis Journal - September 3, 2013 Category: Hematology Authors: Faryal TahirHaris RiazTalha RiazMaaz BadshahIrbaz RiazAmeer HamzaHafsa Mohiuddin Source Type: research

Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: A prospective single-center experience
Conclusions: Implantation of both LAA closure devices can be performed with high success rates in high-risk patients. Postprocedural 6 weeks antithrombotic therapy followed by aspirin therapy needs to be confirmed in a larger study.
Source: Heart Rhythm - August 26, 2013 Category: Cardiology Authors: KR Julian Chun, Stefano Bordignon, Verena Urban, Laura Perrotta, Daniela Dugo, Alexander Fürnkranz, Bernd Nowak, Boris Schmidt Tags: Clinical Source Type: research

Results of percutaneous closure of patent foramen ovale with the GORE ® Septal Occluder
Conclusion. PFO closure with the GSO is accompanied by a high technical success rate and closure rates similar to other currently used devices. The incidence of atrial fibrillation was higher than reported with most other devices. This may be a chance finding but warrants further investigation in larger trials. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - December 10, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Meike Knerr, Stefan Bertog, Laura Vaskelyte, Ilona Hofmann, Horst Sievert Tags: Original Study Source Type: research

Results of percutaneous closure of patent foramen ovale with the GORE® septal occluder
ConclusionPFO closure with the GSO is accompanied by a high technical success rate and closure rates similar to other currently used devices. The incidence of AF was higher than reported with most other devices. This may be a chance finding but warrants further investigation in larger trials. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - January 20, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Meike Knerr, Stefan Bertog, Laura Vaskelyte, Ilona Hofmann, Horst Sievert Tags: Valvular and Structural Heart Diseases Source Type: research

Anticoagulation versus placebo for heart failure in sinus rhythm.
CONCLUSIONS: Based on the two major randomised trials (HELAS 2006; WASH 2004), there is no convincing evidence that oral anticoagulant therapy modifies mortality or vascular events in patients with heart failure and sinus rhythm. Although oral anticoagulation is indicated in certain groups of patients with heart failure (for example those with atrial fibrillation), the available data does not support the routine use of anticoagulation in heart failure patients who remain in sinus rhythm. PMID: 24683002 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 28, 2014 Category: Journals (General) Authors: Lip GY, Shantsila E Tags: Cochrane Database Syst Rev Source Type: research